drugset / Trial / NCT02104804

Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

NCT02104804 ↗

Phase 3 Completed 953 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination with Metformin in Chinese Subjects in China with Type 2 Diabetes Who Have Inadequate Glycaemic Control on Insulin Alone or on Insulin in Combination with Metformin

Timeline

Start
2014-05-07
Primary completion
2016-02-26
Completion
2016-02-26

Outcome

Met primary endpoint

registry analysis (superiority or other test); Vs. Placebo Plus Insulin; p <0.001; Difference in Least Squares Mean -0.58 (95% CI -0.72 to -0.45); ANCOVA NCT02104804 ↗

paper Saxagliptin treatment resulted in a greater adjusted mean change in HbA1c from baseline to week 24 than placebo (-0.58%; P < .001), irrespective of metformin use PMID 29144061 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject SAXAGLIPTIN ANHYDROUS Small molecule 5 mg Oral